KALARIS THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
KALARIS THERAPEUTICS, INC. (KLRS) had Debt Securities, Available-for-sale, Amortized Cost of $50.44 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $50.44M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $70.49M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $19.92M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $34.61M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $50.44M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $70.49M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $19.92M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $34.61M 10-Q · filed 2025-11-12 |
| 2024-09-30 | $4.99M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $24.88M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $54.49M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $93.75M 10-K · filed 2025-03-07 |
| 2023-09-30 | $117.76M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $49.67M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $87.04M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $128.04M 10-K · filed 2024-03-15 |
| 2022-09-30 | $140.70M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $101.89M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $101.39M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $46.48M 10-K · filed 2023-02-15 |
| 2021-09-30 | $32.65M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $87.89M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $168.33M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $233.69M 10-K · filed 2022-02-10 |
| 2020-09-30 | $236.25M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $26.07M 10-Q · filed 2020-09-02 |
| 2019-12-31 | $64.92M 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |